ChromaDex Corporation (CDXC)
| Previous Close | 1.7900 |
| Open | 1.7700 |
| Bid | 1.7400 x 800 |
| Ask | 1.7400 x 1400 |
| Day's Range | 1.7100 - 1.7700 |
| 52 Week Range | 1.5100 - 10.5400 |
| Volume | |
| Avg. Volume | 614,009 |
| Market Cap | 118.827M |
| Beta (5Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4250 |
| Earnings Date | Mar 08, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.17 |
- Simply Wall St.
Trade Alert: Hoi Shuen Chau At ChromaDex Corporation (NASDAQ:CDXC), Has Just Spent US$100k Buying A Small Number of Shares
Even if it's not a huge purchase, we think it was good to see that Hoi Shuen Chau, a ChromaDex Corporation...
- Business Wire
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
LOS ANGELES, June 15, 2022--ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several key scientific conferences including the American Society for Nutrition’s (ASN) Nutrition 2022, the International Society of Sports Nutrition (ISSN) annual meeting, and Federation of American Societies for Experimental Biology (FASEB), The NAD+ Metabolism and Signalin
- Business Wire
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
LOS ANGELES, June 10, 2022--ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen® into mainland China. Tru Niagen® features ChromaDex’s proprietary Niagen® (patented nicotinamide riboside or NR) ingredient, which is the world’s most efficient NAD+ (nicotinamide adenine dinucleotide) precursor on the market, particularly over NMN (n
